Peptide bioregulators: delivery and efficacy

Close metadata

Recommended articles:

Clinical outcomes of laser activation of hydraulic permeability of the sclera in the treatment of advanced glaucoma. Russian Annals of Ophthalmology. 2023;(6):19-25

Objective functional monitoring of retinoprotective treatment in diabetic retinopathy. Russian Annals of Ophthalmology. 2024;(1):45-56

The association between myopia and glaucoma. Russian Annals of Ophthalmology. 2024;(1):93-98

Role of point-by-point light sensitivity in the assessment of glaucoma progression. Russian Annals of Ophthalmology. 2024;(2-2):34-42

Influence of corneal curvature and peripheral thickness on tonometry readings. Russian Annals of Ophthalmology. 2024;(2-2):43-50

Thresholds and variability of retinal light sensitivity in each point of the examined visual field. Russian Annals of Ophthalmology. 2024;(2-2):116-122

Factors affecting the hypotensive effect of selective laser trabeculoplasty in primary open-angle glaucoma. Russian Annals of Ophthalmology. 2024;(2):54-62

Structure of pediatric ophthalmic pathology in Uzbekistan. Russian Annals of Ophthalmology. 2024;(2):97-101

The impact of therapy with Mexidol on neurological deficit and functional outcome in patients with ischemic stroke: a systematic review and meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(12-2):49-60

Cognitive impairment in patients with arterial hypertension. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):41-48

Purpose — to compare the neuroprotective properties of retinalamin administered in different ways among open-angle glaucoma patients with compensated intraocular pressure. Material and methods. The study included 498 patients (eyes) with initial, moderate and advanced stages of glaucoma. Patients were divided into 3 groups: group I (n=110) received 5 mg intramuscular and 5 mg retrobulbar injections of retinalamin; group II (n=171) received 5 mg retrobulbar injection of retinalamin; group III received 5 mg intramuscular injection of retinalamin. The overall treatment dose contained 50 mg of retinalamin. All the patients underwent tonometry and static perimetry. Patients of group II with initial glaucoma and patients of group III with moderate glaucoma also underwent contrast sensitivity tests. The examinations were conducted before the treatment, and on months 3 and 6. Results. Visual acuity did not change significantly. In group I, after 3 months of treatment total threshold retinal sensitivity increased by 122 dB in patients with initial glaucoma, by 166 dB in moderate and by 124 dB in advanced glaucoma. Positive trend was observed in patients with initial and moderate stages of glaucoma by month 6. In group II, total threshold retinal sensitivity increased by 123 dB in initial glaucoma and by 110 dB in moderate; the result did not change by month 6. No significant changes were observed in patients with advanced glaucoma. In group III, total threshold retinal sensitivity increased by 142 dB in initial glaucoma, by 274 dB in moderate and by 148 dB in advanced glaucoma. Regression began on the sixth month. In group II, patients with initial glaucoma were observed to have decreased sensorimotor reaction times to achromatic stimuli within the studied areas of central visual field. In group III, patients with advanced glaucoma were also observed to have decreased sensorimotor reaction times to achromatic stimuli detected within 1° and 5° areas from the fixation point, but not in the 10° area. Conclusion. Retinalamin is most effective in initial and moderate glaucoma stages. Intramuscular, retrobulbar and combined administration methods have comparable efficacy.

Keywords:

glaucoma

neuroprotection

retinalamin

Authors:

Erichev V.P.

FGBU "Nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ" RAMN, Moskva

Lovpache Dzh.N.

FGBU "Moskovskiĭ NII glaznykh bolezneĭ im. Gel'mgol'tsa" Minzdravsotsrazvitiia Rossii

Yaremenko T.V.

I.M. Sechenov First Moscow State Medical University, Department of Ophthalmology, 8-2 Trubetskaya St., Moscow, Russian Federation, 119991

List of references:

Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev. 2001;52(1):37-48. https://doi.org/10.1016/s0169-409x(01)00193-4
Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995;36(9):1893-1903.
Watsky MA, Jablonski MM, Edelhauser HF. Comparison of conjunctival and corneal surface areas in rabbit and human. Curr Eye Res. 1988;7(5):483-486. https://doi.org/10.3109/02713688809031801
Van Ooteghem MM. Factors influencing the retention of ophthalmic solutions on the eye surface. In: Saettone M.S., Bucci G., Speiser P., editors. Ophthalmic drug delivery. 11. Padova: Liviana Press; 1987.
Anselm GMJ, Chorągiewicz T, Ozimek M, Grieb P, Rejdak R. Drug bioavailability from topically applied ocular drops. Does drop size matter? Ophthalmology Journal. 2016;1(1):29-35. https://doi.org/10.5603/OJ.2016.0005
Achouri D, Alhanout K, Piccerelle P, Andrieu V. Recent advances in ocular drug delivery. Drug Dev Ind Pharm. 2013;39(11):1599-1617. https://doi.org/10.3109/03639045.2012.736515
Chang SC, Lee VH. Nasal and conjunctival contributions to the systemic absorption of topical timolol in the pigmented rabbit: implications in the design of strategies to maximize the ratio of ocular to systemic absorption. J Ocul Pharmacol. 1987;3(2):159-169.
Sanford M. Preservative-free latanoprost eye drops in patients with primary open-angle glaucoma/ocular hypertension. Clin Drug Investig. 2014;34(7):521-528. https://doi.org/10.1007/s40261-014-0203-4
Williamson TH, Harris A. Ocular blood flow measurement. Br J Ophthalmol. 1994;78(12):939-945. https://doi.org/10.1136/bjo.78.12.939
Duvvuri S, Majumdar S, Mitra AK. Drug delivery to the retina: challenges and opportunities. Expert Opin Biol Ther. 2003;3(1):45-56. https://doi.org/10.1517/14712598.3.1.45
Kim JH, Kim JH, Kim KW, Kim MH, Yu YS. Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity. Nanotechnology. 2009;20(50):505101. https://doi.org/10.1088/0957-4484/20/50/505101
Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, Kompella UB. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther. 2009;16(5):645-659. https://doi.org/10.1038/gt.2008.185
Olsen TW, Aaberg SY, Geroski DH, Edelhauser HF. Human sclera: thickness and surface area. Am J Ophthalmol. 1998;125(2):237-241. https://doi.org/10.1016/s0002-9394(99)80096-8
Weijtens O, Feron EJ, Schoemaker RC, Cohen AF, Lentjes EG, Romijn FP, van Meurs JC. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol. 1999;128(2):192-197. https://doi.org/10.1016/s0002-9394(99)00129-4
Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis. 2008;14:150-160.
Cheruvu NP, Kompella UB. Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch’s layer. Invest Ophthalmol Vis Sci. 2006;47(10):4513-4522. https://doi.org/10.1167/iovs.06-0404
Nesterov AV, Basinsky SN. New method of drug delivery into the posterior part of Tenon space. Vestnik oftal’mologii. 1991;107(5):49-51. (In Russ.).
Cellini M, Pazzaglia A, Zamparini E, Leonetti P, Campos EC. Intravitreal vs. subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular edema. BMC Ophthalmol. 2008;8:5. https://doi.org/10.1186/1471-2415-8-5
Egorov AE, Kats DV, Baeva NG, Movsisyan AB. The method of targeted delivery of drugs to the posterior segment of the eye. RMJ Klinicheskaya Oftalmologiya. 2018;18(1):26-29. (In Russ.).
Jackson TL, Antcliff RJ, Hillenkamp J, Marshall J. Human retinal molecular weight exclusion limit and estimate of species variation. Invest Ophthalmol Vis Sci. 2003;44(5):2141-2146. https://doi.org/10.1167/iovs.02-1027
Durairaj C, Shah JC, Senapati S, Kompella UB. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res. 2009;26(5):1236-1260. https://doi.org/10.1007/s11095-008-9728-7
Meredith TA. Antibiotics and antifungals. In: Zimmerman T.J., editor. Textbook of Ocular Pharmacology. Philadelphia: Lippincott-Raven Publishers; 1997.
Ghazi NG, Abboud EB, Nowilaty SR, Alkuraya H, Alhommadi A, Cai H, Hou R, Deng WT, Boye SL, Almaghamsi A, Al Saikhan F, Al-Dhibi H, Birch D, Chung C, Colak D, LaVail MM, Vollrath D, Erger K, Wang W, Conlon T, Zhang K, Hauswirth W, Alkuraya FS. Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial. Hum Genet. 2016;135(3):327-343. https://doi.org/10.1007/s00439-016-1637-y
Spraul CW, Lang GE, Grossniklaus HE, Lang GK. Histologic and morphometric analysis of the choroid, Bruch’s membrane, and retinal pigment epithelium in postmortem eyes with age-related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes. Surv Ophthalmol. 1999;44(suppl 1):10-32. https://doi.org/10.1016/s0039-6257(99)00086-7
Cheruvu NP, Amrite AC, Kompella UB. Effect of eye pigmentation on transscleral drug delivery. Invest Ophthalmol Vis Sci. 2008;49(1):333-341. https://doi.org/10.1167/iovs.07-0214
Kuroyedov AV, Brzhesky VV, Krinitsyna EA. Traditional, unfairly forgotten, rarely used and promising drug delivery methods in ophthalmology: a clinical interpretation (part 1). Rossiyskiy oftlmologicheskiy zhurnal. 2019;12(2):83-95. (In Russ.). https://doi.org/10.21516/2072-0076-2019-12-2-83-95
Retinalamin. Neuroprotektsiya v oftalmologii. Pod red. Maksimova I.B., Neroeva V.V. SPb.: Nauka Publ.; 2007. (In Russ.).
Crick RP, Vogel R, Newson RB, Shipley MJ, Blackmore H, Palmer A. et al. The visual field in chronic simple glaucoma and ocular hypertension: is character, progress, relationship to the level of intraocular pressure and response to treatment. Eye. 1989;3:536.
Khavinson VK, Trofimova SV. Peptidnye bioregulatory v oftalmologii. SPb.: Nauka Publ.; 2004. (In Russ.).
Schwartz M. Neurodegeneration and neuroprotection in glaucoma: development of a therapeutic neuroprotective vaccine: the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2003;44:1407-1411. https://doi.org/10.1167/iovs.02-0594

Close metadata